Immutep Ltd (AU:IMM) has released an update.
Immutep Ltd has announced encouraging Phase IIb trial results for its immuno-oncology combination of eftilagimod alfa with KEYTRUDA, showing improved response rates in treating first-line head and neck cancer compared to KEYTRUDA alone, across all levels of PD-L1 expression. The most notable results were seen in patients with high PD-L1 expression, with a 31.0% response rate. These positive outcomes will lead the company to discuss potential regulatory paths and have been accepted for presentation at an upcoming ESMO Virtual Plenary session.
For further insights into AU:IMM stock, check out TipRanks’ Stock Analysis page.
